Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + VCd followed by isatuximab + lenalidomide maintenance in newly diagnosed multiple myeloma with severe renal impairment
2021-004895-32Phase 2Active
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, bortezomib, cyclophosphamide, dexamethasone and lenalidomide in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Renal response rate. Started Feb 2022; status: active.
02
Drugs
isatuximabbortezomibcyclophosphamidedexamethasonelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-004895-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004895-32.